Parkinson's Disease (PD)Phase 2TAME-PD:NCT07464028
Terazosin And Metabolic Energetics in Parkinson's Disease
A Phase 2 study testing Terazosin 5 MG in people with Parkinson's Disease (PD), run by Ergun Y. Uc at 1 site in United States.
Trial summary
This study investigates if Terazosin can improve metabolism in PD. Read more about this study
- Who is it for?
- Ages 50 to 80 years
- Conditions the study is for
- Parkinson's Disease (PD)
- What is being tested?
- Terazosin 5 MG
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jul 2028to 1 Jul 2031
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Parkinson's disease
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Assessing Target Engagement for Terazosin in Parkinson's Disease (TZPD2)
This study investigates if Terazosin can improve metabolism in PD.
- Conditions
- Parkinson's Disease (PD)
- Being tested
- Terazosin 5 MG, Placebo
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Terazosin 5 MGDrug
This drug increases glycolysis in Parkinson's disease.
PlaceboDrug
Placebo control for Terazosin
| Study group | Role | What they receive |
|---|---|---|
| Active arm | Experimental | Terazosin 5 mg Receives: Drug: Terazosin 5 MG |
| Placebo | Placebo comparator | Placebo Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
ATP
Changes in whole-blood ATP relative to baseline at 6 weeks and 1.5 years
Measured: at 1.5 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Mar 2026
- Study start1 Jul 2028 (estimated)
- Primary completion1 Jul 2030 (estimated)
- Study completion1 Jul 2031 (estimated)
Why it stopped: Study not funded
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Parkinson's Disease (PD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ergun Y. Uc
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Ergun Y. Uc, University of Iowa
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07464028
- Sponsor's protocol ID
- 202510685
- Acronym
- TAME-PD:
- Status last verified
- Mar 2026
- First submitted
- 5 Mar 2026
- Last updated
- 9 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: We will share de-identified data after study completion.
Publications
Schultz JL, Gander PE, Workman CD, Boles Ponto LL, Cross S, Nance CS, Groth CL, Taylor EB, Ernst SE, Xu J, Uc EY, Magnotta VA, Welsh MJ, Narayanan NS. A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults. J Parkinsons Dis. 2025 Nov;15(7):1253-1263. doi: 10.1177/1877718X251356503. Epub 2025 Aug 10.
PubMed 40785306Cai R, Zhang Y, Simmering JE, Schultz JL, Li Y, Fernandez-Carasa I, Consiglio A, Raya A, Polgreen PM, Narayanan NS, Yuan Y, Chen Z, Su W, Han Y, Zhao C, Gao L, Ji X, Welsh MJ, Liu L. Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. J Clin Invest. 2019 Oct 1;129(10):4539-4549. doi: 10.1172/JCI129987.
PubMed 31524631Simmering JE, Welsh MJ, Liu L, Narayanan NS, Pottegard A. Association of Glycolysis-Enhancing alpha-1 Blockers With Risk of Developing Parkinson Disease. JAMA Neurol. 2021 Apr 1;78(4):407-413. doi: 10.1001/jamaneurol.2020.5157.
PubMed 33523098Schultz JL, Brinker AN, Xu J, Ernst SE, Tayyari F, Rauckhorst AJ, Liu L, Uc EY, Taylor EB, Simmering JE, Magnotta VA, Welsh MJ, Narayanan NS. A pilot to assess target engagement of terazosin in Parkinson's disease. Parkinsonism Relat Disord. 2022 Jan;94:79-83. doi: 10.1016/j.parkreldis.2021.11.022. Epub 2021 Nov 27.
PubMed 34894470Simmering JE, Welsh MJ, Schultz J, Narayanan NS. Use of Glycolysis-Enhancing Drugs and Risk of Parkinson's Disease. Mov Disord. 2022 Nov;37(11):2210-2216. doi: 10.1002/mds.29184. Epub 2022 Aug 22.
PubMed 36054705Weber MA, Sivakumar K, Tabakovic EE, Oya M, Aldridge GM, Zhang Q, Simmering JE, Narayanan NS. Glycolysis-enhancing alpha1-adrenergic antagonists modify cognitive symptoms related to Parkinson's disease. NPJ Parkinsons Dis. 2023 Mar 2;9(1):32. doi: 10.1038/s41531-023-00477-1.
PubMed 36864060Hart A, Aldridge G, Zhang Q, Narayanan NS, Simmering JE. Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men. Neurology. 2024 Jul 23;103(2):e209570. doi: 10.1212/WNL.0000000000209570. Epub 2024 Jun 19.
PubMed 38896813
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessing Target Engagement for Terazosin in Parkinson's Disease (TZPD2)
- ClinicalTrials.gov ID
- NCT07464028
- Acronym / sponsor ID
- TAME-PD: / 202510685
- Conditions
- Parkinson's Disease (PD)
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- SuspendedReason stopped: Study not funded
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Ergun Y. UcUniversity, hospital or other
- Study start
- 1 Jul 2028 (estimated)
- Primary completion
- 1 Jul 2030 (estimated)
- Study completion
- 1 Jul 2031 (estimated)
- First posted
- 11 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study investigates if Terazosin can improve metabolism in PD.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active arm | Experimental | Drug: Terazosin 5 MGTerazosin 5 mg |
| Placebo | Placebo comparator | Drug: PlaceboPlacebo |
Who may qualify
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Terazosin 5 MGThis drug increases glycolysis in Parkinson's disease. | Drug | Active arm |
| PlaceboPlacebo control for Terazosin | Drug | Placebo |
Primary outcome
ATP
Time frame: at 1.5 year
Changes in whole-blood ATP relative to baseline at 6 weeks and 1.5 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2026.
- Background: PubMed 40785306Schultz JL, Gander PE, Workman CD, Boles Ponto LL, Cross S, Nance CS, Groth CL, Taylor EB, Ernst SE, Xu J, Uc EY, Magnotta VA, Welsh MJ, Narayanan NS. A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults. J Parkinsons Dis. 2025 Nov;15(7):1253-1263. doi: 10.1177/1877718X251356503. Epub 2025 Aug 10.
- Background: PubMed 31524631Cai R, Zhang Y, Simmering JE, Schultz JL, Li Y, Fernandez-Carasa I, Consiglio A, Raya A, Polgreen PM, Narayanan NS, Yuan Y, Chen Z, Su W, Han Y, Zhao C, Gao L, Ji X, Welsh MJ, Liu L. Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. J Clin Invest. 2019 Oct 1;129(10):4539-4549. doi: 10.1172/JCI129987.
- Background: PubMed 33523098Simmering JE, Welsh MJ, Liu L, Narayanan NS, Pottegard A. Association of Glycolysis-Enhancing alpha-1 Blockers With Risk of Developing Parkinson Disease. JAMA Neurol. 2021 Apr 1;78(4):407-413. doi: 10.1001/jamaneurol.2020.5157.
- Background: PubMed 34894470Schultz JL, Brinker AN, Xu J, Ernst SE, Tayyari F, Rauckhorst AJ, Liu L, Uc EY, Taylor EB, Simmering JE, Magnotta VA, Welsh MJ, Narayanan NS. A pilot to assess target engagement of terazosin in Parkinson's disease. Parkinsonism Relat Disord. 2022 Jan;94:79-83. doi: 10.1016/j.parkreldis.2021.11.022. Epub 2021 Nov 27.
- Background: PubMed 36054705Simmering JE, Welsh MJ, Schultz J, Narayanan NS. Use of Glycolysis-Enhancing Drugs and Risk of Parkinson's Disease. Mov Disord. 2022 Nov;37(11):2210-2216. doi: 10.1002/mds.29184. Epub 2022 Aug 22.
- Background: PubMed 36864060Weber MA, Sivakumar K, Tabakovic EE, Oya M, Aldridge GM, Zhang Q, Simmering JE, Narayanan NS. Glycolysis-enhancing alpha1-adrenergic antagonists modify cognitive symptoms related to Parkinson's disease. NPJ Parkinsons Dis. 2023 Mar 2;9(1):32. doi: 10.1038/s41531-023-00477-1.
- Background: PubMed 38896813Hart A, Aldridge G, Zhang Q, Narayanan NS, Simmering JE. Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men. Neurology. 2024 Jul 23;103(2):e209570. doi: 10.1212/WNL.0000000000209570. Epub 2024 Jun 19.
- Individual participant dataSharing planned: Yes. We will share de-identified data after study completion.
Related trials for Parkinson's Disease (PD)
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingObservational study
Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation
Parkinson Disease
Not yet recruiting
Unilateral and Staged Bilateral Pallidothalamic Tractotomy Using Exablate MRgFUS in Advanced Parkinson's Disease.
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Terazosin 5 MG in people with Parkinson's Disease (PD), run by Ergun Y. Uc at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: paused, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ATP (time frame: at 1.5 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07464028, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026.